Search
for
Sort by
Research 211–240 of 1000+
- Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
- Janus Kinase inhibitors in dermatology: a review
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Alopecia Areata and Alopecia Areata Incognita
- Evaluation of Effectiveness of Bio-Micro Injection in Treating Alopecia Universalis: A Non-Randomized Interventional Study
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
- Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Tofacitinib for the treatment of lichen planopilaris: A case series
- Alopecia Areata Possibly Secondary to COVID-19 Vaccine
- SnapshotDx Quiz: September 2018
- 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
- Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
- Janus kinase inhibitors for alopecia areata
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Topical tofacitinib for the treatment of alopecia areata affecting facial hair
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment
- Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results